Company Encyclopedia
View More
name
GlucoTrack
GCTK.US
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc.
1.392 T
GCTK.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Glucotrack Reports Q3 2025 Results and Strategic Progress

    Glucotrack, Inc. reported Q3 2025 results, highlighting a reduced net loss due to decreased revaluation expenses. The company secured $3 million via a convertible promissory note and a $20 million equity line of credit. Strategic plans include submitting an Investigational Device Exemption to the FDA in 2026. Cash reserves are expected to fund operations through Q1 2026.

    Tip Ranks·
    US
    GCTK
    -2.23%
    Tip Ranks·
    US
    GCTK
    -2.23%

    notice_summary_ytd.revenue_title

    LB filings·
    US
    GCTK
    -2.23%
    LB filings·
    US
    GCTK
    -2.23%

    GlucoTrack | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    GCTK
    -2.23%
    LB filings·
    US
    GCTK
    -2.23%

    GlucoTrack Inc. Held Shareholder Meeting

    GlucoTrack Inc. held a special meeting of stockholders on November 7, 2025, after an initial adjournment on October 31, 2025. The meeting was adjourned and cancelled due to lack of a quorum, resulting in no proposals being approved and no business conducted.

    Reuters·
    US
    GCTK
    -2.23%
    Reuters·
    US
    GCTK
    -2.23%

    GlucoTrack Adjourns Shareholder Meeting Due to Lack of Quorum

    GlucoTrack Inc. has adjourned its special meeting of stockholders, originally set for October 31, 2025, due to insufficient quorum, with only 16.4% of shares represented. Stockholders voted 136,928 in favor of the adjournment, with 8,655 against and 1,923 abstentions. The meeting will reconvene on November 7, 2025, to vote on the Issuance Proposal, with only shareholders of record as of September 23, 2025, eligible to vote. This information is based on a report published via EDGAR by GlucoTrack Inc.

    Reuters·
    US
    GCTK
    -2.23%
    Reuters·
    US
    GCTK
    -2.23%
    © 2025 Longbridge｜Disclaimer